Facial paralysis is a restriction of the facial movement due to nerve damage. Facial nerve paralysis is characterized by unilateral facial weakness. Some other symptoms include loss of taste, hyperacusis, and decreased salivation and tear secretion.
The global facial paralysis market is majorly driven by the high prevalence of cardiovascular diseases, the launch of technologically advanced devices, increasing inflammation rates, increasing rate of strokes, and growing penetration by market players. Additionally, factors such as the increasing approvals for facial paralysis, government initiatives and support, and rising reimbursement coverage for cardiologic anomalies are likely to drive the market.
Factors that are likely to hamper the growth of the market are product failures and recalls.
Segments
The global facial paralysis market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the market is segmented into bell’s palsy, Ramsay Hunt syndrome, and Lyme disease.
On the basis of diagnosis, the market is segmented into electromyography, computerized tomography, and magnetic resonance imaging.
On the basis of treatment, the market is segmented into medications, physical therapy,
On the basis of medications, the market is further sub-segmented into corticosteroids and antiviral drugs.
On the basis of end-user, the market is segmented into hospitals and clinics, specialty centers, and research centers.
Key Players
Some of the key players in the facial paralysis market are Boston Scientific, BioControl Medical, Cerebomed, Cyberonics, Astellas Pharma Inc., Sucampo Pharmaceuticals, Inc., and Novartis AG, among others.
Request Customization
Get a Sample
Get a Sample
Request Customization